Author

E. M. da Silva

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:statistical model· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

B. Weigelt· 2 shared H. Dopeso· 2 shared J. S. Reis-Filho· 2 shared A. Fushimi· 1 shared A. Koff· 1 shared A. Nasrazadani· 1 shared A. Safonov· 1 shared A. V. Lee· 1 shared

Activity by Year

2023-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Weigelt

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Spatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations

O. S. Shah, A. Nasrazadani, J. Foldi, J. M. Atkinson, C. G. Kleer, P. F. McAuliffe, T. J. Johnston, W. Stallaert, E. M. Da Silva, P. Selenica, H. Dopeso, F. Pareja, D. Mandelker, B. Weigelt, J. S. Reis-Filho, , S. Oesterreich

This study uses spatial molecular profiling to show that mixed invasive ductal-lobular breast cancers have distinct molecular subtypes, oncogenic signatures, and mutations in different tumor regions, leading to prognostic uncertainty and therapeutic challenges.

bioRxiv · Sep 9, 2023Cancer Biology

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion

R. Kudo, A. Safonov, E. M. da Silva, Q. Li, H. Shao, M. Will, A. Fushimi, H. Nakshatri, J. S. Reis-Filho, S. Goel, A. Koff, B. Weigelt, Q. J. Khan, P. Razavi, S. Chandarlapaty

The paper identifies TP53 loss and MDM2 amplification as factors associated with poor long-term response to CDK4/6 inhibition in breast cancer and shows that CDK2 inhibition can overcome this resistance.

bioRxiv · Aug 25, 2023Cancer Biology

FOXK2 amplification and overexpression promotes breast cancer development and chemoresistance

Y. Yu, W.-M. Cao, F. Cheng, Z. Shi, L. Han, J.-L. Yi, E. M. da Silva, H. Dopeso, H. Chen, J. Yang, X. Wang, C. Zhang, H. Zhang

This study identifies FOXK2 amplification and overexpression in breast cancer, showing its role in promoting tumor growth, chemoresistance, and synergistic therapeutic responses when targeted with PI3KCA inhibitors.

bioRxiv · May 28, 2023 · PreprintCancer Biology